Keywords
diabetes mellitus, diabetic polyneuropathy, neurometry, threshold of current sensitivity.
How to Cite
Garnytska, A., & Mankovsky, B. (2013). Risk factors for diabetic neuropathy development identified by neurometry method. Endokrynologia, 18(2), 55-59. Retrieved from https://endokrynologia.com.ua/index.php/journal/article/view/392
Abstract
Practical application of neurometry method allows to determine the nerve damage more precisely and diagnose diabetic polyneuropathy at early preclinic stages. The results of the study demonstrate in patients with diabetic neuropathy a decreased sensitivity in all nerve fibers under study, that is directly proportional to disease duration, patient’s age and gender, type of diabetes mellitus therapy. This may suggest a relationship between the injury of different
sensitive nerve fibers in diabetes mellitus and all the factors under study in this work.
References
1. Martin C.L. Neuropathy among the Diabetes Control and Complications Trial Cohort 8 years after trial completion // Diabetes Care. 2006, 29, 340-344.
2. Ekberg K., Brismar T., Johansson B.L. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy // Diabetes Care. 2007, 30, 71-76.
3. Herman W.H., Kennedy L. Underdiagnosis of peripheral neuropathy in type 2 diabetes // Diabetes Care. 2005, 28, 1480-1481.
4. Boulton A.J., Vinik A.I., Arezzo J.C. Diabetic neuropathies: a statement by the American Diabetes Association // Diabetes Care. 2005, 28, 956-962.
5. Sumner C.J., Sheth S., Griffin J.W. et al. The spectrum of neuropathy in diabetes and impaired glucose tolerance // Neurology. 2003, 60, 108-111.
6. Casellini C.M., Vinik A.I. Clinical manifestations and current treatment options for diabetic neuropathies // Endocr. Pract. 2007, 13 (5), 550-566.
7. Vinik A., Erbas T., Pfeifer M.A. et al. Diabetic autonomic neuropathy. In: Porte D., Sherwin R.S., Baron A. [eds]. Ellenberg & Rifkin’s, Diabetes Mellitus. 6th ed. New
York, NY: McGraw-Hill, 2003, p. 789-804.
8. Tesfaye S., Chaturvedi N., Simon E.M. et al. Vascular risk factors and diabetic neuropathy // New Engl. J. Med. 2005, 352, 4, 341-350.
9. Masson E.A., Veves A., Fernando D., Boulton A.J.M. Current perception thresholds: a new, quick, and reproducible method for the assessment of peripheral
neuropathy in diabetes mellitus // Diabetologia. Vol. 1989, 32, 724-728.
10. Masson E.A., Boulton A.J.M. The Neurometer: validation and comparison with conventional tests for diabetic neuropathy // Diab. Med. 1991, 8, S63-S66.
2. Ekberg K., Brismar T., Johansson B.L. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy // Diabetes Care. 2007, 30, 71-76.
3. Herman W.H., Kennedy L. Underdiagnosis of peripheral neuropathy in type 2 diabetes // Diabetes Care. 2005, 28, 1480-1481.
4. Boulton A.J., Vinik A.I., Arezzo J.C. Diabetic neuropathies: a statement by the American Diabetes Association // Diabetes Care. 2005, 28, 956-962.
5. Sumner C.J., Sheth S., Griffin J.W. et al. The spectrum of neuropathy in diabetes and impaired glucose tolerance // Neurology. 2003, 60, 108-111.
6. Casellini C.M., Vinik A.I. Clinical manifestations and current treatment options for diabetic neuropathies // Endocr. Pract. 2007, 13 (5), 550-566.
7. Vinik A., Erbas T., Pfeifer M.A. et al. Diabetic autonomic neuropathy. In: Porte D., Sherwin R.S., Baron A. [eds]. Ellenberg & Rifkin’s, Diabetes Mellitus. 6th ed. New
York, NY: McGraw-Hill, 2003, p. 789-804.
8. Tesfaye S., Chaturvedi N., Simon E.M. et al. Vascular risk factors and diabetic neuropathy // New Engl. J. Med. 2005, 352, 4, 341-350.
9. Masson E.A., Veves A., Fernando D., Boulton A.J.M. Current perception thresholds: a new, quick, and reproducible method for the assessment of peripheral
neuropathy in diabetes mellitus // Diabetologia. Vol. 1989, 32, 724-728.
10. Masson E.A., Boulton A.J.M. The Neurometer: validation and comparison with conventional tests for diabetic neuropathy // Diab. Med. 1991, 8, S63-S66.
Downloads
Download data is not yet available.